# A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma

> **NCT00102609** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 41 (actual)

## Conditions studied

- Soft Tissue Sarcoma
- Sarcoma
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Trabectedin
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00102609
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2013-01-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102609, "A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00102609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*